Navigation Links
Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology published by Wiley-Blackwell.

TNF is a cytokine (substance secreted by immune system cells) that regulates the body's immune system and is involved in inflammation. TNF inhibitors (or TNF blockers) are a class of therapies used to reduce inflammation in chronic inflammation such as RA. The common immunosuppressant drugs and those included in the study are Remicade, HumiraTM, and Enbrel. As these therapies are used to treat chronic inflammatory illnesses, the long-term inhibition of TNF raises concerns for increased risk of infections and cancer.

This study, one of the largest and longest population-based assessments of cancer risks associated with immunosuppressive therapy, included data from several Swedish databases including the Biologics Register, the Cancer Register, and the Early RA Register. Researchers identified and analyzed data from 6,366 patients who started anti-TNF therapy between January 1999 and July 2006. Data from patients using TNF inhibitors was compared with other groups of RA patients61,160 not taking medication, 4015 using methotrexate (the gold standard in RA treatment) and 4,015 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF inhibitors).

Results show there were 240 first primary cancers diagnosed during the 25,693 person-years of follow-up in the patients using anti-TNF therapy who had no history of cancer at the onset of immunosuppressant treatment. When compared to the larger national RA cohort who did not receive TNF inhibitors or have a history of cancer, the relative risk of anti-TNF therapy was 1.00 and remained unchanged for those taking immunosuppressant drugs for up to 6 years. "Our research indicates the overall cancer risk is the same for RA patients on immunosuppressant therapies and those not taking medications for the disease," confirmed Dr. Askling, but adds that "given several remaining uncertainties, continued vigilance remains prudent."


Contact: Dawn Peters

Related medicine news :

1. CD200 stifles anti-tumor immunity
2. A new light on the anti-tumor mechanisms of Scutellaria barbata
3. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
4. Short-term stress enhances anti-tumor activity in mice, Stanford study shows
5. Massive necrosis after trans-catheter treatment is more common in the presence of tumor capsule
6. Popular osteoporosis drugs triple risk of bone necrosis
7. Link between treating osteoporosis with bisphosphonates and incidence of bone necrosis examined
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. USC dentist links Fosomax-type drugs to jaw necrosis
10. Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center
11. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Post Your Comments:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Pixel Film ... customizable media panels to choose from, the possibilities are endless. Users have full control ... With the ProPanel: Pulse masking effects, users are sure to get heads to turn. ...
(Date:11/27/2015)... ... 2015 , ... The rapid speed at which Americans are ... care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more ... forgotten part of this equation: 80 percent of medical care occurs in the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
Breaking Medicine Technology: